Inogen Announces First Quarter 2019 Financial Results and Updates 2019 Guidance
- Q1 2019 Sales Revenue up 14.1% Over the Same Period in 2018 -
GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month period ended March 31, 2019.
First Quarter 2019 Highlights
Total revenue of $90.2 million, up 14.1% over the same period in 2018
- Sales revenue of $84.8 million, up 15.3% over the same period in 2018
- Rental revenue of $5.4 million, down 1.5% from the same period in 2018
- Total gross margin of 49.2%, compared to 47.7% in the same period in 2018
- GAAP net income of $5.3 million, compared to a $10.8 million in the same period in 2018
- Total units sold were 50,400, an increase of 5,000, or 11.0%, over the same period in 2018
“The first quarter of 2019 was a tough quarter for us given the decline in domestic business-to-business sales and the increased direct-to-consumer sales and marketing expenditures,” said Scott Wilkinson, Inogen President and Chief Executive Officer. “We believe there is still a large opportunity for portable oxygen concentrator adoption worldwide; however, there are patient access issues given the current reimbursement environment and the restructuring challenges that some providers are facing in converting their oxygen business to a non-delivery model. As a result, we are focused on multiple initiatives to drive sales and marketing efficiencies and build a more predictable revenue stream over time.”
First Quarter 2019 Financial Results
Total revenue for the three months ended March 31, 2019 rose 14.1% to $90.2 million from $79.1 million in the same period in 2018. Direct-to-consumer sales rose 35.9% over the same period in 2018, primarily due to an increase in the number of sales representatives and associated consumer advertising. Domestic business-to-business sales declined 7.0% from the same period in 2018, primarily due to a decline in sales to the Company’s private label partner. These sales to the Company’s private label partner declined primarily due to one large national homecare provider who had significantly reduced orders in the first quarter of 2019 as compared to the same period in 2018. Specifically, this provider accounted for revenue of $0.7 million in the first quarter of 2019, down from $9.3 million in the first quarter of 2018. Excluding this provider, demand remained strong from traditional HME customers. International business-to-business sales in the first quarter of 2019 increased 17.1% (22.3% on a constant currency basis) from the comparative period in 2018, primarily due to robust European demand. Rental revenue in the first quarter of 2019 was $5.4 million compared to $5.5 million in the first quarter of 2018, representing a decline of 1.5%, primarily due to an 11.5% decline in patients on service, partially offset by higher revenue per patient.
Total gross margin was 49.2% in the first quarter of 2019 versus 47.7% in the comparative period in 2018. Sales gross margin was 50.4% in the first quarter of 2019 versus 49.8% in the first quarter of 2018. The sales gross margin increase was primarily due to a favorable mix shift towards higher gross margin direct-to-consumer sales versus business-to-business sales and a reduction in cost of goods sold per unit compared to the first quarter of 2018. The favorable mix was partially offset by lower average selling prices in both the international business-to-business and direct-to-consumer channels, while domestic business-to-business average selling prices were flat. Rental gross margin was 30.8% in the first quarter of 2019 versus 20.0% in the first quarter of 2018. The increase in rental gross margin was primarily due to increased rental revenue per patient on service and lower depreciation expense.
Total operating expense increased to $39.6 million, or 43.8% of revenue, in the first quarter of 2019 versus $29.0 million, or 36.7% of revenue, in the first quarter of 2018.
Operating expense included research and development expense of $1.7 million in the first quarter of 2019, which was up from the $1.4 million in the comparative period in 2018, primarily due to increased product development costs. Sales and marketing expense increased to $28.2 million in the first quarter of 2019 versus $18.0 million in the comparative period in 2018, primarily due to increased advertising expenditures and increased personnel-related expenses primarily at the Company’s Cleveland facility. General and administrative expense increased to $9.7 million in the first quarter of 2019 versus $9.6 million in the comparative period in 2018, primarily due to increased personnel-related expenses, but partially offset by decreased bad debt expense, primarily due to the adoption of ASU 2018-19 that requires reclassification of rental bad debt expense to be charged to rental revenue.
Operating income for the three months ended March 31, 2019 declined 44.2% to $4.9 million, or 5.4% of revenue, down from $8.7 million, or 11.0% of revenue, in the first quarter of 2018, primarily due to higher sales and marketing expense.
In the first quarter of 2019, the Company reported an income tax expense of $0.8 million, compared to an income tax benefit of $1.1 million reported in the first quarter of 2018. Inogen’s income tax expense in the first quarter of 2019 included a $0.6 million benefit in provision for income taxes related to excess tax benefits recognized from stock-based compensation compared to a $3.3 million benefit in the first quarter of 2018. Excluding the stock-based compensation benefit, Inogen’s non-GAAP effective tax rate was 23.1% in the first quarter of 2019 versus 22.5% in the first quarter of 2018. A reconciliation of GAAP and non-GAAP measures is included in the accompanying tables attached hereto.
In the first quarter of 2019, the Company reported GAAP net income of $5.3 million compared to GAAP net income of $10.8 million in the first quarter of 2018. Earnings per diluted common share was $0.24 in the first quarter of 2019 versus $0.48 in the first quarter of 2018.
Financial Outlook for 2019
Inogen is reducing its full year 2019 total revenue guidance to $405 to $415 million, down from $430 to $440 million, representing growth of 13.1% to 15.9% versus 2018 full year results. While the Company still expects direct-to-consumer sales to be its fastest growing channel, it plans to slow the pace of hiring in 2019 and place more emphasis on sales representative productivity. Inogen still expects international business-to-business sales to have a solid growth rate, but now expects domestic business-to-business sales to have a slightly negative growth rate. Given the difficult growth comparisons Inogen faces in the domestic business-to-business channel, the restructuring challenges of some providers, and its rental plan, it expects negative growth in the domestic business-to-business channel in the second quarter of 2019 compared to the second quarter of 2018, with modest growth in the back half of 2019 compared to the back half of 2018. Due to the ongoing restructure challenges some HME providers face, the Company plans to continue to look for ways to partner with providers to drive portable oxygen concentrator adoption. Inogen now plans to slightly change its rental intake criteria to accept more new rental patient additions to increase access to patients who otherwise could not obtain a portable oxygen concentrator from their current homecare provider. Since rental reimbursement revenue is recognized monthly compared to the mostly immediate revenue recognition of direct-to-consumer sales, the Company does not expect a meaningful rental revenue benefit from increasing its new rental setups until next year and beyond. While Inogen expects rental revenue to take time to ramp, the Company believes it can improve its close rate and lead usage by slightly changing its intake criteria on rental patients. Inogen continues to expect rental revenue to grow modestly in 2019.
The Company is reducing its full year 2019 GAAP net income guidance range to $36 to $38 million, down from $40 to $44 million, compared to 2018 GAAP net income of $51.8 million. This decrease in GAAP net income guidance range is primarily due to an estimated reduction in revenue and a decrease in estimated benefit in provision for income taxes related to excess tax benefits recognized from stock-based compensation from $4 million to $1 million, due to Inogen’s current stock price and fewer expected option exercises in 2019. When excluding the benefit from the estimated $1 million decrease in provision for income taxes expected in 2019 from stock-based compensation deductions, the Company still expects a non-GAAP effective tax rate of approximately 24% in 2019.
Inogen is reducing its full year 2019 operating income guidance range to $42 to $44 million, down from $46 to $50 million, representing growth of 10.8% to 16.1% versus 2018 full year results.
Inogen is reducing its full year 2019 Adjusted EBITDA guidance range to $66 to $68 million, down from $67 to $71 million, representing growth of 7.7% to 11.0% versus 2018 full year results.
The Company also expects net positive cash flow for 2019 with no additional equity capital required to meet its current operating plan, in spite of additional investments in rental assets. However, the Company expects lower cash flow than in 2018 as the Company increases rental investments and expects lower cash provided by stock option exercises.
Individuals interested in listening to the conference call today at 1:30pm PT/4:30pm ET may do so by dialing (855) 238-8123 for domestic callers or (412) 317-5217 for international callers. Please reference Inogen (INGN) to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/.
A replay of the call will be available beginning May 7, 2019 at 3:30pm PT/6:30pm ET through 3:30pm PT/6:30pm ET on May 14, 2019. To access the replay, dial (877) 344-7529 or (412) 317-0088 and reference Access Code: 10131253. The webcast will also be available on Inogen's website for one year following the completion of the call.
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.
Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
For more information, please visit www.inogen.com.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding anticipated growth opportunities; expectations for all revenue channels for full year 2019; hiring expectations; changes in the Company’s rental criteria, the anticipated impact of such changes, and the timing of realizing such impact; the expected impact of the lower decrease in provision for income taxes related to excess tax benefits recognized from stock-based compensation for full year 2019; and financial guidance for 2019, including revenue, GAAP net income, operating income, Adjusted EBITDA, net cash flow, non-GAAP effective tax rates, and the need for equity financing. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks arising from the possibility that Inogen will not realize anticipated revenue; the impact of reduced reimbursement rates; the possible loss of key employees, customers, or suppliers; and intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products. In addition, Inogen's business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business operating results are contained in its Annual Report on Form 10-K for the year ended December 31, 2018, and in its other filings with the Securities and Exchange Commission. Additional information will also be set forth in Inogen’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, to be filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.
Use of Non-GAAP Financial Measures
Inogen has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three months ended March 31, 2019 and March 31, 2018. Management believes that non-GAAP financial measures, taken in conjunction with U.S. GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of Inogen's core operating results. Management uses non-GAAP measures to compare Inogen's performance relative to forecasts and strategic plans, to benchmark Inogen's performance externally against competitors, and for certain compensation decisions. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Inogen's operating results as reported under U.S. GAAP. Inogen encourages investors to carefully consider its results under U.S. GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between U.S. GAAP and non-GAAP results are presented in the accompanying table of this release. For future periods, Inogen is unable to provide a reconciliation of non-GAAP measures without unreasonable effort as a result of the uncertainty regarding, and the potential variability of, the amounts of interest income, interest expense, depreciation and amortization, stock-based compensation, provisions for income taxes, and certain other infrequently occurring items, such as acquisition related costs, that may be incurred in the future.
|Consolidated Balance Sheets|
|(amounts in thousands)|
|March 31,||December 31,|
|Cash and cash equivalents||$||190,236||$||196,634|
|Accounts receivable, net||41,525||37,041|
|Deferred cost of revenue||346||359|
|Income tax receivable||2,555||2,655|
|Prepaid expenses and other current assets||9,263||7,108|
|Total current assets||321,756||314,583|
|Property and equipment, net||21,998||22,341|
|Intangible assets, net||3,411||3,755|
|Operating lease right-of-use asset||5,936||—|
|Deferred tax asset - noncurrent||29,296||30,130|
|Liabilities and stockholders' equity|
|Accounts payable and accrued expenses||$||24,731||$||26,786|
|Warranty reserve - current||3,734||3,549|
|Operating lease liability||2,061||—|
|Deferred revenue - current||5,283||4,451|
|Income tax payable||111||392|
|Total current liabilities||43,752||46,585|
|Warranty reserve - noncurrent||6,023||5,981|
|Operating lease liability - noncurrent||4,920||—|
|Deferred revenue - noncurrent||11,379||11,844|
|Deferred tax liability - noncurrent||227||232|
|Other noncurrent liabilities||—||832|
|Additional paid-in capital||255,226||249,194|
|Accumulated other comprehensive income||860||724|
|Total stockholders' equity||321,894||310,424|
|Total liabilities and stockholders' equity||$||388,195||$||375,898|
|Consolidated Statements of Comprehensive Income|
|(amounts in thousands, except share and per share amounts)|
|Three months ended|
|Cost of revenue|
|Cost of sales revenue||42,067||36,948|
Cost of rental revenue, including depreciation of $1,705 and $2,165
for the three months ended, respectively
|Total cost of revenue||45,793||41,324|
|Research and development||1,669||1,416|
|Sales and marketing||28,201||18,038|
|General and administrative||9,681||9,573|
|Total operating expense||39,551||29,027|
|Income from operations||4,858||8,700|
|Other income (expense)|
|Other income (expense)||(120||)||444|
|Total other income, net||1,214||987|
|Income before provision (benefit) for income taxes||6,072||9,687|
|Provision (benefit) for income taxes||770||(1,071||
|Other comprehensive income (loss), net of tax|
|Change in foreign currency translation adjustment||(137||)||108|
|Change in net unrealized gains (losses) on foreign currency hedging||84||(249||
|Less: reclassification adjustment for net (gains) losses included in net income||176||172|
|Total net change in unrealized gains (losses) on foreign currency hedging||260||(77||
|Change in net unrealized gains (losses) on marketable securities||13||(19||
|Total other comprehensive income, net of tax||136||12|
|Basic net income per share attributable to common stockholders (1)||$||0.24||$||0.51|
|Diluted net income per share attributable to common stockholders (1)||$||0.24||$||0.48|
Weighted-average number of shares used in calculating net income
per share attributable to common stockholders:
|Basic common shares||21,750,305||21,026,154|
|Diluted common shares||22,534,885||22,295,213|
|(1)||Reconciliations of net income attributable to common stockholders basic and diluted can be found in Inogen’s Quarterly Report on Form 10-Q to be filed with the Securities and Exchange Commission.|
|Supplemental Financial Information|
|(in thousands, except units and patients)|
|Three months ended|
|Revenue by region and category|
|Business-to-business domestic sales||$||26,061||$||28,016|
|Business-to-business international sales||19,803||16,906|
|Direct-to-consumer domestic sales||38,954||28,662|
|Direct-to-consumer domestic rentals||5,384||5,467|
|Additional financial measures|
|Net rental patients as of period-end||26,200||29,600|
|Reconciliation of U.S. GAAP to Other Non-GAAP Financial Measures|
Three months ended
|Non-GAAP EBITDA and Adjusted EBITDA||2019||2018|
|Provision (benefit) for income taxes||770||(1,071||)|
|Depreciation and amortization||2,794||2,993|
|Adjusted EBITDA (non-GAAP)||$||11,118||$||15,518|
Three months ended
|Non-GAAP provision (benefit) for income taxes and effective tax rate||2019||
|Income before provision (benefit) for income taxes||$||6,072||$||9,687|
|Provision (benefit) for income taxes||770||(1,071||)|
|Effective tax rate||12.7||%||-11.1||%|
|Provision (benefit) for income taxes||$||770||$||(1,071||)|
|Excess tax benefits from stock-based compensation||633||3,252|
|Provision for income taxes (non-GAAP)||$||1,403||$||2,181|
|Income before provision for income taxes||$||6,072||$||9,687|
|Provision for income taxes (non-GAAP)||1,403||2,181|
|Effective tax rate (non-GAAP)||23.1||%||22.5||%|
|Three months ended|
|March 31, 2019||March 31, 2018|
|Non-GAAP international constant currency revenue||(using 2018 FX rates)||(using 2017 FX rates)|
|International revenues (GAAP)||$||19,803||$||16,906|
|Foreign exchange impact||941||(1,553||)|
|International constant currency revenues (non-GAAP)||$||20,744||$||15,353|
|International revenue growth (GAAP)||17.1||%||48.0||%|
|International constant currency revenue growth (non-GAAP)||22.3||%||34.4||%|
Investor Relations Contact:
Matt Bacso, CFA
Source: Inogen, Inc.
Released May 7, 2019